Expression and clinical significance of circ-MFN2 in pancreatic cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LI Siqiao , CHANG Qingtan , LIU Haichao , LIU Shaopeng

Department of Hepatobiliary Surgery, Luoyang Central Hospital, Affiliated to Zhengzhou University, Luoyang, Henan 471000, P. R. China;

Corresponding?author：

LI Siqiao, Email: 316245839@qq.com

Keywords：

pancreatic cancer; circular mitochondrial fusin 2; prognosis

DOI：

10.7507/1007-9424.202009025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression of circular RNA mitochondrial fusin 2 (circ-MFN2) in pancreatic cancer and analyze its correlation with clinicopathological features and prognosis.Methods The expressions of circ-MFN2 miRNA in 55 cases of pancreatic cancer tissues and serum were detected by qRT-PCR, and analyzed the correlation between circ-MFN2 and clinicopathological factors of pancreatic cancer and prognosis. The sensitivity, specificity and accuracy of expression of circ-MFN2 miRNA in the diagnosis of pancreatic cancer were statistically analyzed. ROC curve was used to analyze its efficacy as a biomarker for early diagnosis of pancreatic cancer.Results Compared with paracancerous tissues of pancreatic cancer and serum of healthy control group, circ-MFN2 miRNA was highly expressed in pancreatic cancer tissues and serum, and the difference were all statistically significant (all P<0.05). Chi square test showed that the expression of circ-MFN2 miRNA in pancreatic cancer tissues was not related to age, gender, tumor size, pathological type, and tumor site (P>0.05), but was significantly related to CA19-9 level, TNM stage, tumor differentiation and lymph node metastasis (P<0.05). The sensitivity, specificity and accuracy of expression of circ-MFN2 miRNA for pancreatic cancer were 72.7%, 70.9% and 83.6% respectively, which were all higher than that of CA19-9 (54.5%, 50.9% and 52.7%, P<0.05). Kaplan-Meier analysis showed that the median survival time of pancreatic cancer patients with high expression of circ-MFN2 miRNA was significantly shorter than that of patients with low expression (9.1 months vs 22.3 months, P<0.05). The area under ROC curve of circ-MFN2 miRNA as a serum biomarker for the diagnosis of pancreatic cancer was 0.861 [95%CI (0.775, 1.157), P=0.000]. Cox multivariate analysis showed that the expression of cirC-MFN2 miRNA and lymph node metastasis were independent risk factors for the prognosis of pancreatic cancer patients.Conclusions Circ-MFN2 miRNA is highly expressed in pancreatic cancer tissues, and it is related to the clinical characteristics and prognosis of patients. It is expected to be a new molecular marker to predict the prognosis of pancreatic cancer.

Citation： LI Siqiao, CHANG Qingtan, LIU Haichao, LIU Shaopeng. Expression and clinical significance of circ-MFN2 in pancreatic cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(6): 762-767. doi: 10.7507/1007-9424.202009025 Copy

1.	呂少誠, 賀強, 郎韌, 等. 外科手術在伴有門靜脈系統侵犯的胰腺癌治療中的臨床價值. 中華胰腺病雜志, 2020, 20(4): 254-258.
2.	張太平, 劉悅澤, 曹喆. 新輔助治療背景下胰腺癌擴大切除術的應用價值. 中華外科雜志, 2020, 58(7): 481-485.
3.	Suzuki F, Fujiwara Y, Hamura R, et al. Combination of distance from superior mesenteric artery and serum CA19-9 as a novel prediction of local recurrence in patients with pancreatic cancer following resection. Anticancer Res, 2019, 39(3): 1469-1478.
4.	Li R, Jiang J, Shi H, et al. CircRNA: a rising star in gastric cancer. Cell Mol Life Sci, 2020, 77(9): 1661-1680.
5.	Bunch H. Gene regulation of mammalian long non-coding RNA. Mol Genet Genomics, 2018, 293(1): 1-15.
6.	Li X, Li C, Liu Z, et al. Circular RNA circ-FoxO3 inhibits myoblast cells differentiation. Cells, 2019, 8(6): 616.
7.	高哈爾, 劉芬, 馬峻嶺, 等. 血清環狀 RNA 表達與胃癌關系的探索性研究. 中華流行病學雜志, 2019, 40(12): 1527-1532.
8.	趙靜, 楊興武, 李京濤, 等. 基于高通量測序的肝癌 circRNA-miRNA-mRNA 調控網絡構建及功能富集分析. 臨床肝膽病雜志, 2019, 35(8): 1740-1744.
9.	李麗仙, 何永鵬, 陳霞, 等. 環狀 RNAs 在乳腺癌中的研究進展. 中華乳腺病雜志(電子版), 2020, 14(3): 173-179.
10.	Roitinger E, Hofer M, K?cher T, et al. Quantitative phosphoproteomics of the ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia-mutated and rad3-related (ATR) dependent DNA damage response in Arabidopsis thaliana. Mol Cell Proteomics, 2015, 14(3): 556-571.
11.	Wang L, Long H, Zheng Q, et al. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer, 2019, 18(1): 119.
12.	Li GF, Li L, Yao ZQ, et al. Hsa_circ_0007534/miR-761/ZIC5 regulatory loop modulates the proliferation and migration of glioma cells. Biochem Biophys Res Commun, 2018, 499(4): 765-771.
13.	劉彥, 周超, 楊永學. ciRS-7/miR-7 軸調控腫瘤生長轉移的研究進展. 中國普通外科雜志, 2015, 24(7): 1027-1031.
14.	王婷婷, 韓影, 高芳芳, 等. 環狀RNA circ-SOD2 對腸上皮屏障和潰瘍性結腸炎的作用. 北京大學學報(醫學版), 2019, 51(5): 805-812.
15.	Du WW, Yang W, Li X, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene, 2018, 37(44): 5829-5842.
16.	楊帆. 環狀 RNAcirc-MFN2 在胰腺癌中作為新型診斷生物標志物及其通過 miR-133a-3p/SLC39A4 調控胰腺癌發生發展的機制研究. 中國醫科大學, 2018.
17.	曹鋒, 李非. 腹腔鏡技術在胰腺癌術中再分期的應用. 中華消化外科雜志, 2020, 19(5): 505-510.
18.	雷鵬, 唐超峰, 卜穩平, 等. 溶質載體轉運蛋白 22A3 基因 rs7758229 多態性與胰腺癌預后的關系. 中華實驗外科雜志, 2020, 37(1): 22-24.
19.	言方榮, 朱惠紅, 蔣麗蕓, 等. 生物等效性評價早期停止條件研究. 中國衛生統計, 2017, 34(5): 825-828, 831.
20.	Qian L, Li Q, Baryeh K, et al. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res, 2019, 213: 67-89.
21.	Sabater L, Mu?oz E, Roselló S, et al. Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev, 2018, 68: 124-135.
22.	Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta, 2015, 444: 132-136.
23.	張鶴達, 李偉, 鐘山亮, 等. GEO 數據庫分析環狀 RNA 在乳腺癌組織中的表達. 中國腫瘤外科雜志, 2019, 11(6): 401-405.
24.	劉喻萍, 張莉, 劉詩意, 等. circRNA 生物學特性及其在腫瘤中的研究進展. 武漢大學學報(醫學版), 2020, 41(3): 438-443.
25.	Li D, Yang Y, Li ZQ, et al. Circular RNAs: from biogenesis and function to diseases. Chin Med J (Engl), 2019, 132(20): 2457-2464.
26.	Xu X, Zhang J, Tian Y, et al. CircRNA inhibits DNA damage repair by interacting with host gen. Mol Cancer, 2020, 19(1): 128.
27.	劉乘熙, 王奕智, 郭俊超. 環狀 RNA 的研究進展及胰腺癌中的應用. 中華實驗外科雜志, 2020, 37(1): 5-11.

1. 呂少誠, 賀強, 郎韌, 等. 外科手術在伴有門靜脈系統侵犯的胰腺癌治療中的臨床價值. 中華胰腺病雜志, 2020, 20(4): 254-258.
2. 張太平, 劉悅澤, 曹喆. 新輔助治療背景下胰腺癌擴大切除術的應用價值. 中華外科雜志, 2020, 58(7): 481-485.
3. Suzuki F, Fujiwara Y, Hamura R, et al. Combination of distance from superior mesenteric artery and serum CA19-9 as a novel prediction of local recurrence in patients with pancreatic cancer following resection. Anticancer Res, 2019, 39(3): 1469-1478.
4. Li R, Jiang J, Shi H, et al. CircRNA: a rising star in gastric cancer. Cell Mol Life Sci, 2020, 77(9): 1661-1680.
5. Bunch H. Gene regulation of mammalian long non-coding RNA. Mol Genet Genomics, 2018, 293(1): 1-15.
6. Li X, Li C, Liu Z, et al. Circular RNA circ-FoxO3 inhibits myoblast cells differentiation. Cells, 2019, 8(6): 616.
7. 高哈爾, 劉芬, 馬峻嶺, 等. 血清環狀 RNA 表達與胃癌關系的探索性研究. 中華流行病學雜志, 2019, 40(12): 1527-1532.
8. 趙靜, 楊興武, 李京濤, 等. 基于高通量測序的肝癌 circRNA-miRNA-mRNA 調控網絡構建及功能富集分析. 臨床肝膽病雜志, 2019, 35(8): 1740-1744.
9. 李麗仙, 何永鵬, 陳霞, 等. 環狀 RNAs 在乳腺癌中的研究進展. 中華乳腺病雜志(電子版), 2020, 14(3): 173-179.
10. Roitinger E, Hofer M, K?cher T, et al. Quantitative phosphoproteomics of the ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia-mutated and rad3-related (ATR) dependent DNA damage response in Arabidopsis thaliana. Mol Cell Proteomics, 2015, 14(3): 556-571.
11. Wang L, Long H, Zheng Q, et al. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer, 2019, 18(1): 119.
12. Li GF, Li L, Yao ZQ, et al. Hsa_circ_0007534/miR-761/ZIC5 regulatory loop modulates the proliferation and migration of glioma cells. Biochem Biophys Res Commun, 2018, 499(4): 765-771.
13. 劉彥, 周超, 楊永學. ciRS-7/miR-7 軸調控腫瘤生長轉移的研究進展. 中國普通外科雜志, 2015, 24(7): 1027-1031.
14. 王婷婷, 韓影, 高芳芳, 等. 環狀RNA circ-SOD2 對腸上皮屏障和潰瘍性結腸炎的作用. 北京大學學報(醫學版), 2019, 51(5): 805-812.
15. Du WW, Yang W, Li X, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene, 2018, 37(44): 5829-5842.
16. 楊帆. 環狀 RNAcirc-MFN2 在胰腺癌中作為新型診斷生物標志物及其通過 miR-133a-3p/SLC39A4 調控胰腺癌發生發展的機制研究. 中國醫科大學, 2018.
17. 曹鋒, 李非. 腹腔鏡技術在胰腺癌術中再分期的應用. 中華消化外科雜志, 2020, 19(5): 505-510.
18. 雷鵬, 唐超峰, 卜穩平, 等. 溶質載體轉運蛋白 22A3 基因 rs7758229 多態性與胰腺癌預后的關系. 中華實驗外科雜志, 2020, 37(1): 22-24.
19. 言方榮, 朱惠紅, 蔣麗蕓, 等. 生物等效性評價早期停止條件研究. 中國衛生統計, 2017, 34(5): 825-828, 831.
20. Qian L, Li Q, Baryeh K, et al. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res, 2019, 213: 67-89.
21. Sabater L, Mu?oz E, Roselló S, et al. Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev, 2018, 68: 124-135.
22. Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta, 2015, 444: 132-136.
23. 張鶴達, 李偉, 鐘山亮, 等. GEO 數據庫分析環狀 RNA 在乳腺癌組織中的表達. 中國腫瘤外科雜志, 2019, 11(6): 401-405.
24. 劉喻萍, 張莉, 劉詩意, 等. circRNA 生物學特性及其在腫瘤中的研究進展. 武漢大學學報(醫學版), 2020, 41(3): 438-443.
25. Li D, Yang Y, Li ZQ, et al. Circular RNAs: from biogenesis and function to diseases. Chin Med J (Engl), 2019, 132(20): 2457-2464.
26. Xu X, Zhang J, Tian Y, et al. CircRNA inhibits DNA damage repair by interacting with host gen. Mol Cancer, 2020, 19(1): 128.
27. 劉乘熙, 王奕智, 郭俊超. 環狀 RNA 的研究進展及胰腺癌中的應用. 中華實驗外科雜志, 2020, 37(1): 5-11.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression and clinical significance of circ-MFN2 in pancreatic cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content